NanoVibronix enters LOI with Apogepha to explore European distribution

NanoVibronix announced that it has entered into a non-binding letter of intent, or LOI, with Apogepha Arzneimittel in which both parties will analyze the potential for Apogepha to distribute NanoVibronix’s premiere UroShield product in Germany and other European markets. With a history that dates back over 100 years, Apogepha has established itself as a high quality, dedicated specialist in the field of urology. Under the terms of the LOI, Apogepha will commence a comprehensive market evaluation on how UroShield fits into the pathway of care for patients with long term catheters. The goal of the LOI, and subsequent findings, will be for both NanoVibronix and APOGEPHA to better understand the feasibility of a distribution deal between both companies.